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Initial recommendations were formulated by the co-chairs 
and panel members at a public meeting, and the drafts were 
then disseminated for review sequentially to the writing 
panel, advisory panel, and the public prior to submission. 
The CPG comprises 37 guideline items that address 14 
subjects, including 15 recommendations based on evidence 
rated with strong grades (A/B). Of these, the major 
recommendations are to use analysis of EGFR mutation 
and ALK fusion to select patients with advanced-stage 
adenocarcinoma for EGFR- and ALK-targeted therapy, 
regardless of sex, race, smoking history, or other clinical 
risk factors. These clinical characteristics were found to be 
not specific or sensitive enough to either select a patient for 
a targeted inhibitor, or serve as prerequisites in selecting an 
individual for molecular testing for aberrations in EGFR 
and ALK. Testing for EGFR mutations and ALK fusions 
should also be prioritized over other molecular analysis. 
The present molecular testing guideline to select lung 
cancer patients for EGFR and ALK TKIs was developed 
on limited published data, integrating expert consensus 
opinions, and anticipating regular updates when new 
testing indications or innovative technologies emerge for 
routine clinical implementation. (p. 823)
•	 Four-Year Results of Low-
Dose CT Screening and 
Nodule Management in 
the ITALUNG Trial
15.8% of the 1263 subjects were positive in subsequent 
screening rounds. The rates of screen-detected lung 
cancers were low: 1.5% in subjects at baseline and 
0.5% in subjects at subsequent screening. At least one 
follow-up LDCT was performed in slightly over half of 
the subjects. FDG-PET and FNAB both showed 84% 
to 90% sensitivity and specificity for malignancy. The 
authors concluded that high-risk individuals enrolled 
in LDCT screening were highly compliant throughout 
the screening cycle. However, the low tumor detection 
rate and specificity compromised the efficacy of 
LDCT. This confirms the need for a better defined 
target population and possibly the use of biomarkers 
in risk stratification to improve the cost effectiveness 
of screening. The low rate of surgery for benign 
lesions in this trial indicates that these surgeries could 
be minimized by strict adherence to a management 
protocol including follow-up LDCT with or without 
1-month antibiotic therapy, FDG-PET, and CT-guided 
FNAB. (p. 866)
JTO ANNOUNCES
Considering the number of publications on lung cancers bearing 
EGFR mutations and the rapid pace of ALK related development, 
there is a critical clinical need to establish molecular testing standards 
and recommendations to guide EGFR- and ALK-targeted therapies. 
Three co-chairs, a writing panel, and an advisory panel from the 
College of American Pathologists, International Association for the 
Study of Lung Cancer, and Association for Molecular Pathology were 
selected to critically and systematically review published data and 
develop evidence-based recommendations for the molecular analysis 
of lung cancers for these two predictive biomarkers in a clinical 
practice guideline (CPG). The evidence was gathered through three 
unbiased literature searches, which were reviewed for relevance to the 
recommendations, and formally graded for each recommendation by 
its strength in assisting users of the CPG in clinical decision making. 
ITALUNG is a randomized clinical trial evaluating the efficacy 
of LDCT in lung cancer screening in Italy. This article covers 
the final data from the ITALUNG trial on subjects’ compliance, 
results of low-dose CT (LDCT) screening, and the management 
protocol of the screen-detected suspicious nodules in the active 
arm. Current or former smokers were randomized to receive either 
usual care or four annual LDCT screenings. Procedures included 
in the management protocol were CT-guided fine needle aspiration 
biopsy (FNAB), follow-up LDCT and 2-[18F]fluoro-2-deoxy-D 
glucose positron emission tomography (FDG-PET). Of 1406 
subjects receiving baseline LDCT, 30.3% were positive while 
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•	 Improving the Quality 
of Lung Cancer Care in 
Ontario: The Lung Cancer 
Disease Pathway Initiative
held where regional care providers shared region-
specific data on incidence, stage, treatment compliance, 
wait times, and other lung cancer relevant issues. 
CCO provided funding for possibilities of regional 
improvement based on the data and priorities. As a result 
of this initiative, the lung cancer pathways were refined. 
Available on CCO’s website now are the diagnostic 
pathway and the treatment pathways for SCLC and 
NSCLC, as well as educational materials for dyspnea 
management. There are also Lung Cancer Diagnostic 
Assessment Units/Programs across the province. 
DPM has improved access of lung cancer patients to a 
standardized Edmonton Symptom Assessment System 
to evaluate their symptoms each month. An audit to 
determine the challenge of uniform employment of 
specific evidence-based practices across the province 
is underway. All in all, CCO’s lung cancer DPM has 
raised awareness of Regional Cancer Programs (RCP) 
on lung cancer-specific performance and quality of care. 
Continuous assessment of a broad range of metrics will 
identify the benefits of this initiative. (p. 876)
RESEARCH WATCH:
•	 RHOA-FAK Axis: 
Critical Vulnerability 
of KRAS-Driven Lung 
Adenocarcinomas
Dr. Scaglioni’s group set out to identify vulnerabilities in KRAS-
mutant tumors, which could be exploited for cancer therapy. Cellular 
systems and a mouse model of high-grade lung adenocarcinoma 
induced by a recombinant transgene that allows activation of mutant 
KRAS in the respiratory epithelium, were used to elucidate the 
signaling pathways downstream of mutant KRAS in NSCLC. The 
Cancer Care Ontario (CCO) has incorporated Disease Pathway 
Management (DPM) to its provincial cancer control quality 
improvement initiatives with three goals for specific cancers: to 
share evidence-based best practice, to determine priorities in quality 
improvement and catalyze action, and to monitor performance 
against best practice. The authors described the process and some 
early successes of the establishment of the CCO lung cancer DPM 
since 2009. Five working groups across disciplines were formed 
to focus on prevention, screening, and early diagnosis; diagnosis; 
treatment; palliative care, end-of-life, survivorship; and patient 
experience. The working groups developed quality improvement 
projects from which a “Priorities for Action Report” was generated 
and disseminated across the province. Regional “roadshows” were 
•	 Detection of ALK 
Rearrangement by 
Immunohistochemistry 
in Lung Adenocarcinoma 
and the Identification of a 
Novel EML4-ALK Variant
RT-PCR was used to confirm the fusion variants in ALK 
positive cases by IHC or FISH. The findings indicated 
that all ALK negative cases determined by IHC were 
negative by FISH. All ALK positive cases by IHC were 
also positive by FISH or RT-PCR, except two cases 
that were FISH negative but harbored EML4-ALK 
variant 1 as confirmed by RT-PCR. Taken together, 
IHC can effectively detect ALK rearrangement in 
lung cancer with high sensitivity and specificity. It 
would be a reliable and cost effective tool in routine 
pathologic laboratories to identify patients suitable for 
ALK targeted therapy. In cases where lung cancers 
bearing the translocation and were ALK IHC-positive 
but FISH-negative, treatment with ALK inhibitors could 
be beneficial but further clinical trials are required. The 
study also led to the discovery of a novel variant of 
EML4-ALK (E3:ins53A20) with potent tumorigenicity 
potential in vivo. This variant might be important for 
tumorigenesis of lung cancer and further consolidates the 
role of ALK signaling in lung cancers. (p. 883)
Lung adenocarcinomas bearing the oncogenic driver, EML4-ALK 
fusion gene, are responsive to the treatment of ALK inhibitors. 
However, the gold standard for detection of ALK rearrangement, 
namely fluorescence in situ hybridization (FISH) and RT-PCR, have 
their limitations. Immunohistochemistry (IHC) has been considered 
an alternative to FISH but optimal IHC protocol is needed. The 
authors therefore investigated the reliability of using routine IHC 
staining to detect ALK expression as a means to determine ALK 
rearrangement in lung adenocarcinoma and compared it with FISH. 
In this study, IHC and FISH were used to detect ALK rearrangement 
in 373 lung adenocarcinomas from Chinese patients. Multiplex 
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findings showed that RHOA-focal adhesion kinase (FAK) signaling 
pathway is a critical requirement for the maintenance of high-grade 
lung tumors. Inhibition of RHOA or FAK induces selective cell 
death in mutant KRAS;INK4A/ARF-deficient lung cancer cells, 
and tumor regression specifically in mutant Kras;Cdkn2a-null mice 
bearing the high-grade lung cancer. This study revealed the RHOA-
FAK signaling axis as a novel and critical vulnerability of mutant 
KRAS in NSCLCs that are INK4a/ARF- or TP53-deficient. Also, 
FAK inhibitors exert potent antitumor effects in NSCLCs bearing 
mutant KRAS in association with INK4A/ARF deficiency. This 
information would also provide insights for developing a biomarker 
to guide personalized cancer treatment using FAK inhibitors. Further 
studies in clinical trials using FAK inhibitors are warranted.
Konstantinidou G, Ramadori G, Torti F, et al. RHOA-FAK is a 
required signaling axis for the maintenance of KRAS-driven lung 
adenocarcinomas. Cancer Discov 2013;3:444–457.
•	 Esophageal 
Adenocarcinoma (EAC): 
Dissecting the Mutational 
Complexity by Exome 
and Whole-Genome 
Sequencing
to be a potential mutagenic trigger. Data from whole-exome 
sequencing identified 26 significantly mutated genes, including 
TP53, CDKN2A, SMAD4, ARID1A and PIK3CA which have 
previously been reported in EAC. New mutations found include 
chromatin-modifying factors and candidate contributors SPG20, 
TLR4, ELMO1, and DOCK2. ELMO1 and DOCK2 are upstream 
regulators of the RAC1 GTPase. Functional analyses of EAC-
derived mutations in ELMO1 demonstrated augmented cellular 
invasion. Therefore, RAC1 pathway could potentially play a role 
in EAC tumorigenesis. The current data also suggest that mutation 
could be a potential biomarker, in addition to overexpression and 
genomic amplification of ERBB2, to guide the use of ERBB2-
targeting agents in the treatment of EAC. More functional 
studies of these genes are needed to elucidate their roles in EAC 
tumorigenesis and to determine the underlying cause of the unique 
transversions at AA dinucleotides in EAC.
Dulak AM, Stojanov P, Peng S, et al. Exome and whole-
genome sequencing of esophageal adenocarcinoma identifies 
recurrent driver events and mutational complexity. Nat Genet 
2013;45:478–486.
The increased incidence and poor prognosis of EAC reflect an 
urgent need to better understand the underlying cause for EAC 
and to help with the development of diagnostics or targeted 
therapies. Dulak and colleagues elucidated the genomic 
alterations of 149 EAC cases untreated by chemotherapy or 
radiation before surgery, using whole-exome sequencing of 
paired tumor and normal tissues. Fifteen of these were also 
subjected to whole-genome sequencing. Data from whole-
genome sequencing revealed a mutation profile defined by high 
frequencies of A>C transversions at AA dinucleotide sites (34% 
of the total mutations), which appeared to be unique to EAC. A 
greater fraction of the transversions was found within tubular 
esophagus, which suggests stomach acid in the lower esophagus 
•	 Estrogen Receptor 1 
(ESR1) Expression as 
Prognostic and Predictive 
Marker in Non-Small Cell 
Lung Cancer (NSCLC)
clinical and survival data in a training set (n = 138) and a test 
set (comprising subpopulation from the adjuvant JBR.10 study). 
High ESR1 expression was of significant positive prognostic value 
for early stage NSCLC patients in the training set population 
and in the observational arm of the test set population. Tumors 
with low ESR1 levels showed a benefit from ACT with a 5-year 
survival of 77.8% compared with 33.3% in the observational arm. 
Patients with high ESR 1 levels did not benefit from ACT. It is 
the first report that indicates that ESR1 expression in NSCLC is 
of prognostic value and could also be predictive in this setting. 
Further studies on ESR1 levels in larger cohorts of patients with 
NSCLC are warranted. This finding reflects the possibility to 
clinically stratify NSCLC patients by ESR1 expression in decision 
making on adjuvant therapy. It also prompts further studies to 
evaluate anti-estrogenic agents for treating NSCLC patients 
expressing high level of ESR1.
Brueckl WM, Al-Batran SE, Ficker JH, et al. Prognostic and 
predictive value of estrogen receptor 1 expression in completely 
resected non-small cell lung cancer. Int J Cancer April 12, 2013 
[Epub ahead of print].
Adjuvant cisplatin-based chemotherapy is the accepted standard 
of care for the management of stage II to IIIA completely resected 
NSCLC. Some patients with resected NSCLC are at a high risk 
of relapse after adjuvant chemotherapy (ACT) while some remain 
relapse free without ACT. Hence, prognostic and predictive 
markers for clinical outcome are required. Studies showed a 
correlation between tumors with high expression of estrogen 
receptors and improved response to anti-estrogens or aromatase 
inhibitors in breast cancers. Estrogen receptors are also expressed 
in lung tumors. In this study, the authors evaluated the association 
of estrogen receptor 1 (ESR1) expression with survival in patients 
with completely resected NSCLC. Publicly available gene 
microarray, clinical, and follow-up data from studies in early stage 
NSCLC were used. Expression values were determined against 
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•	 Genome-Wide Analysis 
Links Gene Expression, 
Cancer Cell Invasion and 
Anti-Cancer Compound 
Sensitivity
correlation with paclitaxel, docetaxel, erlotinib, everolimus, and 
dasatinib. This eight-gene signature was validated for its prediction 
for chemosensitivity in 107 independent experiments in 78 tumor 
cell lines (mostly outside the NCI-60 panel). Published clinical 
and molecular data from lung and breast cancer cohorts receiving 
adjuvant chemotherapy were analyzed using the eight-gene 
signature and it predicted relapse-free survival for the lung and 
breast cancer patients. Taken together, this study enhanced the 
NCI-60 model with important in vitro characteristics of cancer and 
revealed a set of genes that are associated to cancer invasion and 
chemosensitivity, which could be used to predict survival in patients 
with lung or breast cancer.
Hsu YC, Chen HY, Yuan S, et al. Genome-wide analysis of three-
way interplay among gene expression, cancer cell invasion and anti-
cancer compound sensitivity. BMC Medicine 2013;11:106.
•	 Anti-HER2 Agents for 
Lung Cancer with a HER2 
Mutation
agents: afatinib, trastuzumab, lapatinib, and masatinib. Progressive 
disease was observed in four patients, disease stabilizations in seven 
patients, and partial responses in eleven patients. Progression-free 
survival for patients with anti-HER2 therapies was 5.1 months. 
Median survival was 89.6 and 22.9 months for early-stage and stage 
IV patients, respectively. Of note, a disease control rate (DCR) of 
93% was observed in trastuzumab-based treatment and a DCR of 
100% with afatinib. Prospective clinical trials will be required to 
confirm the benefit of the anti-HER2 drugs in patients with HER2 
mutations. The findings illustrate the potential of anti-HER2 agents 
in treating patients of this population and underscore the importance 
of screening for HER2 mutations in these patients.
Mazieres J, Peters S, Lepage B, et al. Lung cancer that harbors 
a HER2 mutation: epidemiologic characteristics and therapeutic 
perspectives. J Clin Oncol April 22, 2013 [Epub ahead of print].
The authors conducted a genome-wide analysis to understand the 
molecular profile of invasion heterogeneity in cancer cells and its 
relationship to anti-cancer drug sensitivity. Using the NCI-60 panel, 
they identified 633 invasion-associated (IA) genes by invasion 
assay and Affymetrix gene expression data. The association of 
IA genes to drug sensitivity was evaluated from the analysis of 
chemosensitivty data from 99 anti-cancer compounds with known 
mechanism of action. Eight genes (EGFR, ITGA3, MYLK, RAI14, 
AHNAK, GLS, IL32, and NNMT) were identified with significant 
Patients with NSCLC that harbor HER-2 overexpression 
(approximately 20%) do not respond to anti-HER2 agent, whereas 
those bearing a HER2 mutation (approximately 2–3%) respond to 
these drugs, according to this study. The largest retrospective study 
to date in Europe was conducted by Julien Mazières and colleagues 
to examine the effect of anti-HER2 agents in patients with HER2 
mutation. They identified 65 (1.7%) NSCLC patients with a HER2 
in-frame insertion in exon 20. All 65 tumors were adenocarcinomas 
and 50% were stage IV, mostly women (69%), and 52.3% were 
never-smokers. Sixteen patients, with stage IV lung cancer and prior 
conventional therapy, were treated with one or more anti-HER2 
•	 Dissecting the Genomic 
Profiles on Recurrence in 
Patients with Non–Small-
Cell Lung Cancer (NSCLC) 
by Next-Generation 
Sequencing
(12 patients). Ten patients have tumors bearing two or more 
recurrent alterations. A concordance rate of 94% was determined by 
comparative analysis of recurrent alterations between primary tumor 
and matched metastasis while non-recurrent alterations show a rate 
of 63%. The findings suggest the application of archived primary 
tumors in delineating genomic profiles on recurrence by detecting key 
recurrent alterations in matched metastatic tumors, which could be 
valuable to guide treatment on recurrence.
Vignot S, Frampton GM, Soria JC, et al. Next-generation 
sequencing reveals high concordance of recurrent somatic 
alterations between primary tumor and metastases from patients 
with non-small-cell lung cancer. J Clin Oncol April 29, 2013 [Epub 
ahead of print].
Genomic changes in archived primary NSCLC tumors were compared 
with those in matched metastatic tumors for the genomic profiling of 
recurrence. Matched primary and metastatic tumors from 15 patients 
were evaluated by next-generation sequencing. About 20% of the 
genomic changes identified were known recurrent alterations, of 
which TP53 mutations were the most frequent recurrent alterations 
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•	 Pooled Analysis of KRAS 
Mutation and Subtype in 
Prognosis and Predicting 
Outcome of Early-Stage 
Resected Non–Small-Cell 
Lung Cancer
Twenty four patients with codon 13 mutations appeared to have 
worse outcome from ACT but this needs to be validated despite 
being statistically significant. At this stage, KRAS mutation cannot 
be recommended as a marker in NSCLC patient selection for ACT. 
This was the first report of an association of KRAS mutation status 
with an almost 3-fold risk of developing second primary tumors 
in the OBS cohort. This implicates the potential of KRAS status in 
identifying high risk patients developing second primary tumors 
without ACT, whom might benefit from more intense follow-up.
Shepherd FA, Domerg C, Hainaut P, et al. Pooled analysis of the 
prognostic and predictive effects of KRAS mutation status and 
KRAS mutation subtype in early-stage resected non-small-cell lung 
cancer in four trials of adjuvant chemotherapy. J Clin Oncol April 
29, 2013 [Epub ahead of print].
This study analyzed four trials of adjuvant chemotherapy (ACT) 
versus observation (OBS) to determine the prognostic role of 
KRAS mutation and predictive effects of KRAS codons on survival 
benefit in non-small-cell lung cancer (NSCLC). They explored the 
relationship between KRAS mutation, mutation subtype (codons 
12, 13 and 14), and survival outcome using a multivariate Cox 
model in a population of 1543 patients. The results showed no 
significant prognostic value for KRAS mutations in NSCLC. 
NEWS IN BRIEF:
•	 ESTRO 2013: 
Mathematical Models 
Versus Doctors in 
Prediction of Outcomes 
and Responses to 
Treatment
treatment. They used published mathematical models and incorporated 
previous patients’ information to generate a statistical formula for 
the prediction for future patients. The findings of the study, presented 
at the 2nd Forum of the European Society for Radiotherapy and 
Oncology (ESTRO), demonstrated that mathematical prediction 
models out-perform doctors in the prediction with a better predictive 
value than that of the doctors: 0.71 vs. 0.56 for 2-year survival, 0.76 
vs. 0.59 for dyspnea and 0.72 vs. 0.52 for dysphagia, respectively. The 
negative predictive value was comparable between the models and 
the doctors. Further studies are needed to integrate prediction models 
into standard clinical care as well as to improve models with the latest 
discoveries in genetics and imaging, for instance.
Oberije and her colleagues from the MAASTRO Clinic, Maastricht 
University Medical Center, Maastricht, The Netherlands, compared 
mathematical prediction models with radiation oncologists at 
predicting the outcomes and responses of lung cancer patients to 
•	 Saving $63 Billion in 
Health Care Costs with 
Federal Cigarette Tax 
Increase
cigarette tax by 94 cents would save the country more than $63 
billion in long-term health care spending, which includes more than 
$821 million from fewer smoking-related lung cancer cases over 10 
years. The total federal cigarette tax would be $1.95 per pack under 
the proposed raise. The increase of the federal tax on other tobacco 
products would also take place under the budget proposal, which 
would improve public health and health care savings.
American Cancer Society Cancer Action Network (ACS CAN) 
estimated that the President’s proposal to increase the federal 
•	 A Mathematical Model 
Tells the Future Pathways 
and Timescales of 
Metastatic Lung Cancer
demonstrated the main aspects that determine the future pathways 
and timescales of progression are combined characteristics of the 
primary site and the first metastatic site as a spreader or sponge. Lung 
is a significant self-seeder, in which circulating tumor cells from the 
primary tumor re-enter the primary site. Other significant mechanisms 
of multidirectionality in lung cancer progression are metastasis 
reseeding of the regional and distant lymph nodes and adrenal gland, 
primary lung reseeding through regional lymph nodes, and metastasis 
reseeding of the liver. The model could potentially affect surgical 
decisions in metastatic disease as different outcomes for patients could 
be predicted when the disease site is a spreader or sponge.
A Markov chain/Monte Carlo (MCMC) mathematical model was 
developed by Newton and colleagues for cancer progression based on 
a large set of autopsy data to determine the multidirectional pathways 
and timescales associated with metastasis in lung cancer. The major 
findings, published in Cancer Research, show that metastatic lung 
cancer is a systemic and multidirectional stochastic process. The model 
